The Global Landscape of Tuberculosis Therapeutics

Published Date:

01/31/2019

Source:

Annu Rev Med

Authors:

Tornheim JA, Dooley KE

External link

Original Article

Tuberculosis (TB) is one of the oldest infections afflicting humans yet remains the number one infectious disease killer worldwide. Despite decades of experience treating this disease, TB regimens require months of multidrug therapy, even for latent infections. There have been important recent advances in treatment options across the spectrum of TB, from latent infection to extensively drug-resistant (XDR) TB disease. In addition, new, potent drugs are emerging out of the development pipeline and are being tested in novel regimens in multiple currently enrolling trials. Shorter, safer regimens for many forms of TB are now available or are in our near-term vision. We review recent advances in TB therapeutics and provide an overview of the upcoming clinical trials landscape that will help define the future of worldwide TB treatment.

Events

«

June 2020

»
S
M
T
W
T
F
S
·
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
·
·
·
·

Projects

A smoking cessation trial in HIV/AIDS...

A tobacco prevalence survey and smoking cessation trial among HIV infected patients in South Africa.

Read More

A randomized trial of preventive therapy for...

We are evaluating the efficacy and cost-effectiveness of levofloxacin preventive therapy for adult contacts of MDR TB patients...

Read More

Comparative Effectiveness/Implementation of...

This cluster-randomized trial in 56 rural primary care clinics compares the effectiveness and implementation of three strategies...

Read More

TB Modeling and Analysis Consortium (TB MAC)

Dr. Dowdy serves on the steering committee of an international consortium of TB modelers that aims to improve approaches to TB...

Read More